SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.89-CN¥0.00 (0.0%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
Loading market information…
HKSE · 2552.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 05:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Hua Medicine (Shanghai) Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Hua Medicine (Shanghai) Ltd.’s next earnings report is currently expected on Apr 1, 2027, with estimated earnings per share of HK$0.59. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hua Medicine (Shanghai) Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -HK$0.14-123.55% vs estimate |
| HK$6.95M-99.19% vs estimate |
| Q2 2023 | Aug 24, 2023 | -HK$0.10-125.72% vs estimate | HK$75.69M-88.01% vs estimate |
|---|
| Q4 2022 | Mar 29, 2023 | -HK$0.11-147.34% vs estimate | HK$20.09M-96.51% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.89-CN¥0.00 (0.0%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
HK$42.46-HK$0.54 (-1.26%)
Suzhou Ribo Life Science Co’s quoted price sits in the lower half of its reported 52-week range, 55.68% below the high.
HK$4.96-HK$0.26 (-4.89%)
Ascletis Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.03% below the high.
HK$8.80+HK$0.14 (+1.62%)
TransThera Sciences (Nanjing). Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.42% below the high.
HK$5.68+HK$0.04 (+0.71%)
Laekna, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.69% below the high.
HK$4.84+HK$1.01 (+26.24%)
PegBio Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 93.72% below the high.
HK$14.79+HK$0.79 (+5.64%)
VISEN Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 65.84% below the high.
HK$3.11HK$0.00 (0.0%)
HighTide Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 34.11% below the high.
